The Oncology Pharmacist
Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below and click "Subscribe".
First Name *
Last Name *
Email Address *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

  • Home
  • Issues
    • 2021
      • March 2021 - Vol 14 No 2
      • January 2021 - Vol 14 No 1
    • 2020
      • November 2020, Vol 13, No 6
      • September 2020 - Vol 13 no 5
      • July 2020 - Vol 13 no 4
      • May 2020 - Vol 13 no 3
      • March 2020 - Vol 13 no 2
      • January 2020 - Vol 13 No 1
    • 2019
      • November 2019 - Vol 12 No 4
      • August 2019 - Vol 12 No 3
      • May 2019 - Vol 12 No 2
      • February 2019 - Vol 12 No 1
    • 2018
      • November 2018 - Vol 11 No 3
      • August 2018 - Vol 11 No 2
      • May 2018 - Vol 11 No 1
    • Issue Archive
  • Special Issues
    • Supplements
      • ASK THE EXPERT: First-Line Treatment of Metastatic Non-small cell Lung Cancer
    • Guide to New FDA Approvals
      • 2019 Fourth Annual Guide
      • 2018 Third Annual Guide
      • 2017 Second Annual Guide
      • 2016 First Annual Guide
  • Categories
  • Conference Correspondent
    • Year End Review 2019
  • Web Exclusives
    • Ovarian Cancer Overview
    • All Web Exclusives
    • Drug Updates
    • FDA Approvals, News & Updates
    • In the News
    • Interview with the Innovators
    • Press Releases
    • Online First
    • Media Library
      • Videos
      • Audiocasts
  • Quick Quiz
  • CE
  • About
    • About TOP
    • Advertise
    • Editorial Board
    • Contact Us
    • Resources
    • Submit
      • Author Guidelines
The Oncology Pharmacist

Lung Cancer

Real-World Data for Nivolumab in Patients with Malignant Mesothelioma
2020 Year in Review - Lung Cancer - Lung Cancer
Read More
Trastuzumab Deruxtecan in Patients with HER2-Mutated Advanced NSCLC
2020 Year in Review - Lung Cancer - Lung Cancer
Read More
Pralsetinib and Selpercatinib for NSCLC Patients with RET Gene Fusions
2020 Year in Review - Lung Cancer - Lung Cancer
Read More
Lorlatinib Improves Outcomes Over Crizotinib in First-Line Setting of ALK-Positive NSCLC
2020 Year in Review - Lung Cancer - Lung Cancer
Read More
Combination Ramucirumab and Erlotinib for NSCLC with EGFR Exon 19 or Exon 21 Mutations
2020 Year in Review - Lung Cancer - Lung Cancer
Read More
Capmatinib for Patients with NSCLC with MET Exon 14 Mutation
2020 Year in Review - Lung Cancer - Lung Cancer
Read More
Anti-TIGIT Antibody Tiragolumab plus Atezolizumab in Patients with PD-L1–Selected NSCLC
2020 Year in Review - Lung Cancer - Lung Cancer
Read More
Phase 3 EMPOWER-Lung 1 Study of Cemiplimab in Advanced PD-L1–Positive NSCLC
2020 Year in Review - Lung Cancer - Lung Cancer
Read More
Updated Analysis of PFS Data from Cohort G of KEYNOTE-021 in Nonsquamous NSCLC
2020 Year in Review - Lung Cancer - Lung Cancer
Read More
Durvalumab Demonstrates Sustained Overall Survival in Unresectable Stage III NSCLC
2020 Year in Review - Lung Cancer - Lung Cancer
Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
Page 4 of 11
Results 31 - 40 of 107
 
  • Privacy Policy
  • Terms of Use
  • Home
  • About
  • Subscribe
  • Advertise
  • Contact Us

©2021 Green Hill Healthcare Communications, LLC, an affiliate of The Lynx Group. All rights reserved.
1249 South River Road - Suite 202, Cranbury, NJ 08512

  • Home
  • Issues
    • 2021
      • March 2021 - Vol 14 No 2
      • January 2021 - Vol 14 No 1
    • 2020
      • November 2020, Vol 13, No 6
      • September 2020 - Vol 13 no 5
      • July 2020 - Vol 13 no 4
      • May 2020 - Vol 13 no 3
      • March 2020 - Vol 13 no 2
      • January 2020 - Vol 13 No 1
    • 2019
      • November 2019 - Vol 12 No 4
      • August 2019 - Vol 12 No 3
      • May 2019 - Vol 12 No 2
      • February 2019 - Vol 12 No 1
    • 2018
      • November 2018 - Vol 11 No 3
      • August 2018 - Vol 11 No 2
      • May 2018 - Vol 11 No 1
    • Issue Archive
  • Special Issues
    • Supplements
      • ASK THE EXPERT: First-Line Treatment of Metastatic Non-small cell Lung Cancer
    • Guide to New FDA Approvals
      • 2019 Fourth Annual Guide
      • 2018 Third Annual Guide
      • 2017 Second Annual Guide
      • 2016 First Annual Guide
  • Categories
  • Conference Correspondent
    • Year End Review 2019
  • Web Exclusives
    • Ovarian Cancer Overview
    • All Web Exclusives
    • Drug Updates
    • FDA Approvals, News & Updates
    • In the News
    • Interview with the Innovators
    • Press Releases
    • Online First
    • Media Library
      • Videos
      • Audiocasts
  • Quick Quiz
  • CE
  • About
    • About TOP
    • Advertise
    • Editorial Board
    • Contact Us
    • Resources
    • Submit
      • Author Guidelines